Company intelligence / Profile preview
Oncodesign Precision Medicine
Dijon, Bourgogne-Franche-Comté, Franceoncodesign.com ↗
- Ownership
- Public · ALOPM
- Employees
- ~198
- Development stage
- Phase 1
01
Overview
Oncodesign Precision Medicine has two advanced products in clinical development. OPM‑101 completed a Phase I trial in healthy volunteers with high target engagement and no toxicity; a Phase Ib/IIa trial in patients with chronic immuno-inflammatory digestive diseases and immuno-oncology indications will start in early 2025. OPM‑201 completed a Phase I trial for Parkinson’s disease and was initially licensed to Servier before returning to the portfolio. A third program, OPM‑102 for oncology, remains preclinical. The company leverages proprietary platforms including AI-based target discovery.[4][6][8]
- Therapeutic areas
- GastroenterologyOncologyNeurology
- Modalities
- Small molecule kinase inhibitors (macrocyclic)Radiolabeled biological molecules (theranostics/radiotherapy)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Servier Laboratories (exclusive license on OPM–201/Parkinson’s compound & target discovery collaboration in pancreatic cancer)[6][10]Navigo Proteins GmbH (systemic radiotheranostic agents)[4][6]Other vectorization companies under discussion
04
Financials
- Market cap
- $30B
- Total revenue
- $2.2B
- Enterprise value
- $30.6B
Beyond the preview
Go deeper on Oncodesign Precision Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncodesign Precision Medicine.